Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Follow-Up Questions
Genocea Biosciences Inc (GNCAQ)'in P/E oranı nedir?
Genocea Biosciences Inc 'in P/E oranı 0 'dir
Genocea Biosciences Inc 'in CEO'su kimdir?
Mr. William Clark 2010 'den beri şirketle birlikte olan Genocea Biosciences Inc 'in President 'ıdır.
GNCAQ hissesinin fiyat performansı nasıl?
GNCAQ 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Genocea Biosciences Inc için ana iş temaları veya sektörler nelerdir?
Genocea Biosciences Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
